Technology ID
TAB-4906
Bispecific Antibodies: A Novel Approach to Treating Ebola Virus Infections
E-Numbers
E-090-2021-0
Lead Inventor
Pegu, Amarendra ("Amar")
Lead IC
NIAID
Co-Inventors
Ploquin, Aurelie
Stringham, Christopher
Bai, Ke
DeMouth, Megan
Sullivan, Nancy
Misasi, John
Asokan, Mangaiarkarasi
Mascola, John
Leigh, Kendra
Oloniniyi, Olamide
ICs
NIAID
NCI
Applications
Therapeutics
Diagnostics
Therapeutic Areas
Rare/Neglected Diseases
Infectious Disease
Development Stages
Pre-clinical (in vivo)
Research Products
Human Cell Lines
Antibodies
The described technology pertains to the development of bispecific antibodies targeting the Ebola virus glycoprotein. These antibodies, mAb114 and either S1-4-A09 or its engineered variant S1-4-A09 A80P, demonstrate specificity towards the Ebola virus (EBOV) glycoproteins from different strains, including Kikwit and Bundibugyo. The variant S1-4-A09 A80P retains binding specificity and activity but lacks a glycosylation motif, enhancing manufacturability without compromising function.
Commercial Applications
The BiSp107 antibody technology is poised for application in a range of scenarios that extend beyond the immediate treatment of Ebola virus infection. Its design for use as both a prophylactic and a therapeutic agent broadens its utility significantly. Healthcare workers, military personnel, and individuals in Ebola-endemic regions could benefit from pre-exposure prophylaxis, offering a safeguard against potential outbreaks.
Competitive Advantages
The bispecific antibodies technology offers several competitive advantages over existing treatments for Ebola virus infection. The BiSp107 combines the antigen-binding regions of two monoclonal antibodies, which may result in higher potency and efficacy due to synergistic effects on virus neutralization. This bispecific approach could potentially lead to lower required dosages, enhancing patient compliance and reducing treatment costs.
Licensing Contact: